GlassScriptPhysician profile
Joseph M Haggerty
NPI 1013098870
$564.77
in general payments reported to CMS, 2019-2025
15 companies · $36.57 in 2025
The $36.57 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $34.39 · 2023: $110 · 2024: $383 · 2025: $36.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $515 · Education: $14.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $515.43 |
| Education | $14.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $125.18 | 2021-2024 | Monjuvi, Jakafi |
| Merck Sharp & Dohme LLC | $65.37 | 2024 | Keytruda |
| Gilead Sciences, INC. | $62.84 | 2021-2024 | |
| Mirati Therapeutics, INC. | $48.58 | 2024 | Krazati |
| Genzyme Corporation | $45.18 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $38.70 | 2024 | |
| Array Biopharma INC | $36.57 | 2025 | Mektovi, Braftovi, Tukysa |
| Glaxosmithkline, LLC. | $34.23 | 2024 | Zejula, Jemperli |
| Alexion Pharmaceuticals, INC. | $30.61 | 2024 | Ultomiris |
| Acrotech Biopharma INC. | $22.55 | 2024 | Beleodaq |
| Genentech USA, INC. | $21.44 | 2024 | Venclexta |
| Abbvie INC. | $18.57 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $14.95 | 2023 | Opdualag |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Haggerty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.